Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells

被引:9
作者
Sun, Qifeng [1 ]
Peng, Chuanliang [1 ]
Cong, Bo [1 ]
Hao, Yingtao [1 ]
Guo, Jiazhong [1 ]
Zhao, Yunpeng [1 ]
Zhao, Xiaogang [1 ]
机构
[1] Shandong Univ, Hosp 2, Dept Thorac Surg, 247 Beiyuan St, Jinan 250033, Shandong, Peoples R China
关键词
Lung adenocarcinoma; lymph node; metastasis; Syk; VEGF-C; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; PROTEIN-TYROSINE KINASE; FACTOR RECEPTOR-3; GASTRIC-CANCER; EXPRESSION; LYMPHANGIOGENESIS; CARCINOMAS; MECHANISMS; NECK;
D O I
10.4103/0973-1482.150413
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Aims: Lung cancer has become one of the most dangerous malignant tumors in the world nowadays, whose pathogenesis is complex involving multi-genes and multi-elements. This study aims to investigate the values of spleen tyrosine kinase (Syk) and vascular endothelial growth factor-C (VEGF-C) in lymphangiogenesis and metastasis of lung adenocarcinoma A549 cells. Materials and Methods: The pcDNA3.1-VEGF-C and pLNCX-syk were constructed and transfected into A549 cells. After cells with stable expression were sorted, the level of VEGF-C was tested by RT-PCR and immunohistochemistry and the mRNA of syk was tested by RT-PCR. The cell invasion assay was investigated by transwell chamber in vitro. Restriction enzyme digestion and gel electrophoresis demonstrated successful construction of the pcDNA3.1-VEGF-C. Results: RT-PCR and immunohistochemistry revealed higher expression of VEGF-C in VEGFC-construct-transfected A549 cells than that in controls (P 0.05). Successful construction of the pLNCX-syk was demonstrated by restriction enzyme electrophoresis and sequencing. RT-PCR revealed Syk expression higher in syk-construct-transfected cells than in controls (P 0.05). Conclusions: The results indicate a potential link between the upregulation of Syk and VEGF-C expression and lung adenocarcinoma.
引用
收藏
页码:640 / 644
页数:5
相关论文
共 27 条
[1]   Molecular and cellular mechanisms of lymphangiogenesis [J].
Al-Rawi, MAA ;
Mansel, RE ;
Jiang, WG .
EJSO, 2005, 31 (02) :117-121
[2]   ZD1839 ('Iressa')1,2 as an anticancer agent [J].
Baselga, J ;
Averbuch, SD .
DRUGS, 2000, 60 (Suppl 1) :33-40
[3]   The Syk family of protein tyrosine kinases in T-cell activation and development [J].
Chu, DH ;
Morita, CT ;
Weiss, A .
IMMUNOLOGICAL REVIEWS, 1998, 165 :167-180
[4]  
Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
[5]  
Ding Yong-bin, 2004, Zhonghua Yi Xue Za Zhi, V84, P290
[6]   Molecular and biological properties of vascular endothelial growth factor [J].
Ferrara, N .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (07) :527-543
[7]   The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer [J].
Kajita, T ;
Ohta, Y ;
Kimura, K ;
Tamura, M ;
Tanaka, Y ;
Tsunezuka, Y ;
Oda, M ;
Sasaki, T ;
Watanabe, G .
BRITISH JOURNAL OF CANCER, 2001, 85 (02) :255-260
[8]   Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis [J].
Karkkainen, MJ ;
Petrova, TV .
ONCOGENE, 2000, 19 (49) :5598-5605
[9]   Molecular mechanisms in B cell antigen receptor signaling [J].
Kurosaki, T .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (03) :309-318
[10]   Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase [J].
Li, J ;
Sidell, N .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (01) :14-20